William Jacot

机构：Institut de Recherche en Cancérologie de Montpellier · ORCID：0000-0001-7834-061X

发表论文 476 篇 · 总被引 18541 次 · h-index 52

代表论文

• Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial (2025 · Nature Medicine · 被引 30)
• HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination With Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer (2025 · Journal of Clinical Oncology · 被引 10)
• 600- vs 400-mg First-Line Ribociclib in Hormone Receptor–Positive/ ERBB2 -Negative Advanced Breast Cancer (2025 · JAMA Oncology · 被引 6)
• Prognostic Significance and Predictive Value of Circulating Tumor Cells in Invasive Lobular Breast Carcinoma—An Exploratory Analysis of the STIC CTC Trial (2025 · Clinical Cancer Research · 被引 4)
• Neutropenic events associated with new anticancer treatments, from pathophysiology to practice: a scoping review—NEW Group (Neutropenic Events Working Group) (2025 · Supportive Care in Cancer · 被引 3)
• Real-world treatment patterns and effectiveness after disease progression on CDK4/6 inhibitors for HR-positive/HER2-negative metastatic breast cancer in the ESME-MBC cohort (2025 · ESMO Open · 被引 3)